Canada Life’s Heron Therapeutics HRTX Stock Holding History

Canada Life’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,633	Closed	-$7K	–	2281
2023 Q1	$7K	Hold	4,633	–	–	﹤0.01%	2304
2022 Q4	$12K	Hold	4,633	–	–	﹤0.01%	2315
2022 Q3	$19K	Hold	4,633	–	–	﹤0.01%	2274
2022 Q2	$13K	Hold	4,633	–	–	﹤0.01%	2336
2022 Q1	$28K	Hold	4,633	–	–	﹤0.01%	2288
2021 Q4	$42K	Hold	4,633	–	–	﹤0.01%	2214
2021 Q3	$50K	Hold	4,633	–	–	﹤0.01%	2234
2021 Q2	$72K	Sell	4,633 -1,464	-24%	-$23.3K	﹤0.01%	2162
2021 Q1	$98K	Hold	6,097	–	–	﹤0.01%	2101
2020 Q4	$129K	Hold	6,097	–	–	﹤0.01%	2062
2020 Q3	$90K	Hold	6,097	–	–	﹤0.01%	2060
2020 Q2	$89K	Hold	6,097	–	–	﹤0.01%	2076
2020 Q1	$72K	Hold	6,097	–	–	﹤0.01%	2044
2019 Q4	$142K	Buy	6,097 +1,010	+20%	+$22.3K	﹤0.01%	2001
2019 Q3	$94K	Sell	5,087 -4,500	-47%	-$82.8K	﹤0.01%	1011
2019 Q2	$178K	Hold	9,587	–	–	﹤0.01%	2057
2019 Q1	$234K	Buy	9,587 +1,976	+26%	+$51.7K	﹤0.01%	1834
2018 Q4	$190K	Hold	7,611	–	–	﹤0.01%	1948
2018 Q3	$240K	Buy	7,611 +3,016	+66%	+$112K	﹤0.01%	1933
2018 Q2	$178K	Hold	4,595	–	–	﹤0.01%	2007
2018 Q1	$127K	Sell	4,595 -5,196	-53%	-$118K	﹤0.01%	2092
2017 Q4	$177K	Buy	9,791 +6,799	+227%	+$111K	﹤0.01%	1999
2017 Q3	$48K	Hold	2,992	–	–	﹤0.01%	2341
2017 Q2	$41K	Hold	2,992	–	–	﹤0.01%	2375
2017 Q1	$45K	Hold	2,992	–	–	﹤0.01%	2331
2016 Q4	$39K	Hold	2,992	–	–	﹤0.01%	2381
2016 Q3	$51K	Hold	2,992	–	–	﹤0.01%	2333
2016 Q2	$54K	Hold	2,992	–	–	﹤0.01%	2285
2016 Q1	$57K	Hold	2,992	–	–	﹤0.01%	2071
2015 Q4	$80K	Buy	+2,992	New	+$80K	﹤0.01%	1908

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Canada Life's HRTX Position: Q2 2023 in Review

Canada Life sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 4,633 shares — an estimated $7K sold.

Canada Life first reported a position in HRTX in Q4 2015 and held it in 30 quarters. The position peaked at $240K in Q3 2018. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

Canada Life reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
Canada Life sold 4,633 Heron Therapeutics shares in Q2 2023, an estimated $7K.
Canada Life first reported a position in Heron Therapeutics in Q4 2015 and held it in 30 quarters.
Canada Life's Heron Therapeutics position peaked at $240K in Q3 2018.
149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Canada Life's 13F filing for Q2 2023, filed 10 Aug 2023.